Dr. Katelyn Halpape, BSP, ACPR, PharmD, BCPP

Katelyn is an Associate Professor in the College of Pharmacy and Nutrition at the University of Saskatchewan and a Board Certified Psychiatric Pharmacist. She practices as a clinical pharmacy specialist in mental health and substance use disorders in Saskatoon, Saskatchewan.

Her work focuses on improving care for individuals with substance use disorders through evidence-based pharmacotherapy, interdisciplinary collaboration, and capacity building within healthcare systems. Katelyn has particular expertise in opioid use disorder, including opioid agonist therapy and transitions to buprenorphine/naloxone, as well as harm reduction and patient centred approaches to care.

Her research and clinical work aim to bridge the gap between guideline recommendations and real-world practice, with a focus on improving access to treatment in Saskatchewan. She has led and collaborated on projects exploring barriers to opioid agonist therapy prescribing, the role of pharmacists in addiction medicine, and patient experiences with buprenorphine/naloxone.

In addition to her research, Katelyn is actively involved in teaching and mentorship across pharmacy, medicine, and other health disciplines. She is committed to advancing substance use disorder care through education, collaboration, and system level innovation.

British Columbia Centre on Substance Use Online Addiction Medicine Diploma, 2018

Board Certified Psychiatric Pharmacist (BCPP), 2018

Doctor of Pharmacy (PharmD), University of British Columbia, 2015

Accredited Canadian Hospital Pharmacy Residency (ACPR), 2013

Bachelor of Science in Pharmacy (BSP), University of Saskatchewan, 2012

Halpape K*, Jorgenson D, Rogers M. (March 26, 2026). Patient Perspectives on Buprenorphine/Naloxone for Chronic Non-Cancer Pain: A Qualitative Interview Study. Canadian Journal of Pain. 2026;10(1):1-17.

Wood E, Bright J, Hsu K, Goel N, Ross J, Hanson A, Teed R, Poulin G, Denning B, Corace K, Chase C, Halpape K, Lim R, Kealey T, Rehm J. Updated screening recommendations from the

Canadian guideline for the clinical management of higher-risk drinking and alcohol use disorder committee. Canadian Medical Association Journal. (Accepted March 16, 2026).

Wiebe A, Pecson R, Coupland M, Halpape K*. (May 14, 2025). Role of Pharmacists in Addiction Medicine in Canada’s Publicly Funded Healthcare Systems: A Qualitative Study. Canadian Journal of Hospital Pharmacy. 2025;78(2):e3680. https://doi.org/10.4212/cjhp.3680.

Halpape K. (October 2024). Cannabinoid Drug Interactions: Essential Insights for Pharmacists. Pharmacy Practice+Business. 2024:11(6):15-16. https://issuu.com/ensembleiq/docs/ppb-0624?fr=sZmI4MjYzMDEwNTE.

Halpape K. (January 2024). Unveiling the Hidden Struggle: Pharmacists as Key Allies in Identifying and Treating Alcohol Use Disorder. Pharmacy Practice+Business. 2024;11(1):26-27. https://issuu.com/ensembleiq/docs/ppb-0124_2_?fr=sZTY4NzYzMDEwNTE.

Nguyen T, Bareham J, Halpape K*. (April 01, 2024). Barriers and Facilitators to Family Physicians Prescribing Opioid Agonist Therapy in Primary Care in Saskatchewan. Canadian Family Physician. 2024;70(4):e52-e60. https://doi.org/10.46747/cfp.7004e52.

Wood E, Bright J, Hsu K, Goel N, Ross J, Hanson A, Teed R, Poulin G, Denning B, Corace K, Chase C, Halpape K, Lim R, Kealey T, Rehm J. (October 16, 2023). Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder. Canadian Medical Association Journal. 2023;195(40): E1364-79. https://doi.org/10.1503/cmaj.230715.

Co-author of patient education materials on buprenorphine/naloxone and substance use

Developer of educational content on substance use disorders for pharmacy and medical learners